The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Future of pancreatic cancer: KRAS targeting, biomarkers, and combination therapy strategies
Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, discusses the future of pancreatic cancer treatment, focusing on biomarker-driven approaches. Dr O’Connor highlights that KRAS drives 95% of pancreatic cancer cases, with opportunities for new strategies in KRAS wild-type patients. They emphasize identifying optimal tumor drivers and biomarkers, particularly KRAS, as promising targets. The future likely involves combination therapies targeting both the tumor microenvironment and KRAS inhibitors simultaneously. This integrated approach represents hope for improving outcomes in this deadly gastrointestinal malignancy through personalized, biomarker-guided treatment strategies. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.”
